The kinetics of tumor markers have been integrated into the assessment of treatment response in certain advanced cancers, such as prostate-specific antigen in prostate cancer and CA125 in ovarian cancer [25,41,42]. This evidence concerns the gene KLK3 and ovarian carcinoma.